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nloaded fromControl of the architecture and electromagnetic behavior of nanostructures offers the possibility of designing and
fabricating sensors that, owing to their intrinsic behavior, provide solutions to new problems in various fields. We
show detection of peptides in multicomponent mixtures derived from human samples for early diagnosis of breast
cancer. The architecture of sensors is based on a matrix array where pixels constitute a plasmonic device showing a
strong electric field enhancement localized in an area of a few square nanometers. The method allows detection of
single point mutations in peptides composing the BRCA1 protein. The sensitivity demonstrated falls in the picomo-
lar (10−12 M) range. The success of this approach is a result of accurate design and fabrication control. The residual
roughness introduced by fabrication was taken into account in optical modeling and was a further contributing
factor in plasmon localization, increasing the sensitivity and selectivity of the sensors. This methodology developed
for breast cancer detection can be considered a general strategy that is applicable to various pathologies and other
chemical analytical cases where complex mixtures have to be resolved in their constitutive components.htt
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ag.org/INTRODUCTION
The control of the top-down organization of matter at nanoscale is a
mature field where convergence of design and accurate fabrication can
be obtained in a reproducible way (1–8). Therefore, designing devices
for applications, especially in areas such as few-molecules detection, is
now possible.
Here, we propose the use of organized plasmonic nanostructures, in
particular a matrix array of self-similar chains (SSCs) (9–12), to solve
the molecular composition of complex mixture solutions. We intend
to address early disease detection (13–15), in particular early detection
of breast cancer (16, 17). The conceptual scheme of this paper interlaces
the design, fabrication, and measurement of the architecture of the cho-
sen device, as well as sample preparation. For measurement, we com-
bine SSC nanostructures with Raman spectroscopy. In fact, these kinds of
devices, thanks to strong plasmon localization, have the enhanced sensi-
tivity and specificity needed for solving complex mixtures.
The combination of plasmonic nanostructures and Raman spec-
troscopy is recognized as a powerful analytical approach (18). Nevertheless,
for single-molecule or few-molecules detection, the method has strong
limitations when used as a brute force for complex constructs (such as
a mixture of different kinds of molecules) (9, 10), as in early disease
detection or, in general, in molecular medicine. These limitations are
easily explained by the fact that Raman spectra from a mixture of sev-
eral kinds of macromolecules or from high–molecular weight proteinsdo not show any specific signatures necessary to solve or distinguish
each component or basic molecular group constituting high–molecular
weight proteins. That is, Raman bands originating from different com-
ponents of a mixture tend to overlap one another, and the attribution
of Raman peaks and bands to each molecule or to the building block
of molecules’ constituents is almost impossible. In particular, the meth-
od fails when the number of components is higher than 5 (19) or in
proteins with high molecular weight.
We propose, on the basis of human proteins implicated in breast
cancer development, a way to detect a mixture of peptides unambig-
uously representing the signature of a tumor. This method, designed for
detecting biomarkers in the early stage of cancer, was applied to hu-
man samples. Moreover, in a mixture of peptides, we demonstrated spec-
ifically down to the single amino acid level. This result was achieved
by retaining the high sensitivity of a single SSC and by achieving high
selectivity for SSCs combined in an m × n matrix array. In particular,
we designed a matrix where each SSC is the sensitive pixel of the array
(Fig. 1) and total pixel interrogation is used to reconstruct the molec-
ular composition of the mixture. By setting an appropriate dilution,
each pixel detects a reduced number of molecular species in the mix-
ture, compatible with the solution concentration and diffusion laws.
The whole mixture can be reconstructed by reading the Raman
spectra of a dried solution on all m × n matrix elements.THE ANALYTICAL APPROACH
The success of this method lies in two peculiar aspects of the SSC:
first, the electric field generated in each SSC is strongly spatially con-
fined (hotspot) to a region of a few square nanometers; and, second,
Raman enhancement is high enough (about 107) to allow for the de-
tection of a few molecules falling in the hotspot region. With this
strategy, our device has the appropriate sensitivity and selectivity
necessary to solve complex mixtures. A further element is that1 of 9
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 the device is compatible with biomolecular methods used to extract pep-
tide content from the protein domain of interest. The peptides
extracted from the protein domain differ in the substitution of a single
amino acid, which is the cause of missense mutations in the BRCA1
protein. BRCA1 is a tumor suppressor gene whose germline mutations
predispose to breast and ovarian cancers (20, 21). Particularly, the liter-
ature has shown that a woman carrying a germline mutation of BRCA1Coluccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015has an 85% risk of developing breast and ovarian cancers, and it is es-
timated that about 5 to 10% of all breast cancers are caused by inher-
itance of dominant disease genes (22). BRCA1 encodes a 220-kD
nuclear phosphoprotein, which interacts with many proteins and is
involved in responses to DNA damage, cell cycle control, transcription
regulation, apoptosis, and protein degradation. The protein is functionally
organized in domains located at the N terminus and C terminus of theFig. 1. Scheme of the whole process from peptide extraction to Raman detection. (A) A mixture of peptides is extracted from the BRCT domain
derived from the BRCA1 protein. (B) The mixture is collected in aqueous solution at a concentration of 100 pM. (C to E) A drop is deposited and dried on a
matrix array of SSCs (each chain is a pixel). (F) The whole content of peptides is spread over the matrix, and some (three different types per pixel, on
average) are deposited in the smallest gap. These are the only ensembles per pixel that contribute to the Raman signal. (G) Representative Raman signal
from pixel i,j of the matrix array composed of, on average, three different types of peptides.2 of 9





 molecule (23, 24). In particular, the C-terminal region of BRCA1 has
two amino acid repeats, both named BRCT, characterized by hydro-
phobic clusters of amino acids, which are thought to stabilize the
three-dimensional (3D) structure of the protein.
The C-terminal BRCT domain (Fig. 1A) is involved in the stability
of the BRCA1 protein’s conformation and plays a role in transcrip-
tional control and DNA repair by interacting with other cellular
factors (25–27). For this reason, the loss of normal functions mediated
by the BRCT domain, resulting from inherited mutations, is thought
to increase the risk of developing breast and ovarian cancers (see Sup-
plementary Materials, section 1).
It has been shown that one missense mutation in the BRCT domain
is a crucial event because it alters the hydrophobic patch and modifies
protein folding, stability, and functionality. One of the first cancer-
associated missense mutations studied is M1775R peptide, which is
characterized by the substitution of a methionine (a highly hydro-
phobic amino acid) with arginine (a highly hydrophilic amino acid)
at the fixed sequential position 1775 (28). This mutation results in a
complete loss of the bound protein. Some functional studies have
shown that the effects of M1775R missense mutation in BRCA1 are
specifically related to the position of the amino acid involved in the
mutation and probably depend on the charge switch of the mutated
amino acid (29). This mutation could affect different intracellular path-
ways that may play a key role in the pathogenesis of hereditary breast
cancer. Identification of specific alterations in protein profiles asso-
ciated with the BRCA1 protein offers an opportunity for early diag-
nosis of breast and ovarian cancers.
The direct detection of a single amino acid point mutation in the
BRCA1 protein through Raman or other spectroscopic techniques is an
impossible task because the signature in the spectra is washed out by other
complexmoleculargroups in theprotein.For this reason,weusedmolecularColuccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015methods based on digestive enzyme technology to extract the relative set of
peptides contained in the BRCA1-BRCT protein domain. In this way, de-
tection ofmutation is transformed into amulticomponentmixture analysis.
In the present work, we obtained both in vitro wild-type and mu-
tated BRCA1-BRCT protein domains. The mutated form is charac-
terized by a missense mutation known as M1775R, which has been
described previously. The two protein domains were digested by Glu-C
enzyme and fractionated by micro–high-performance liquid chroma-
tography (HPLC). Peptides obtained from the wild-type and mutated
domains are referred to as M1775 and M1775R, respectively.
The two fractions containing the M1775 peptide plus 10 other pep-
tides (for a total mix of 11 peptides) and the M1775R peptide plus 13
other peptides (for a total mix of 14 peptides) (Table 1) were analyzed
by Raman spectroscopy using a 10 × 10 SSC array (Fig. 1, B to G). In the
following, we describe SSC design, fabrication, and electromagnetic
behavior, followed by detailed accounts of spectroscopic measurements.SSC DESIGN AND FABRICATION
The proposed device consists of three noble metal nanospheres of ap-
propriate diameter and interdistance relation, as explained by Li et al. (9).
The device, firstly proposed by Li et al. (9), shows two spatial regions with
plasmonic field localization. In particular, an intense hotspot (Fig. 2D)
is localized in the smallest gap (between the smallest sphere and the
middle sphere). The footprint area of the hotspot is comparable with
the smallest gap. Moreover, the relative position between the nano-
spheres, calculated by Li et al. (9), was further optimized to maximize
the ratio of the electric field in the hotspot to the electric field in the
middle gap. However, from the point of view of fabrication, the SSC
device presents a challenge because it is necessary to control the o
n
 
ag.org/Table 1. Fractional peptide content of M1775 (wild type) and M1775R (mutated). The point mutation (arginine replaces methionine in peptide 1)
is underlined.June 12, Number of
peptidesFractional M1775 (wild type)
sequence peptidesComposition (%)
(error, 8%)Fractional M1775R (mutated)
sequence peptidesComposition (%)
(error, 8%) 20201 ICCYGPFTNMPTDQLE 11.18 ICCYGPFTNRPTDQLE 6.362 APVVTREWVLD 7.85 SDPSEDRAPE 9.923 ADALYTNPAQARE 2.56 TSYLPRQDLE 5.914 TAANLHAPVILAGTPGTFT HAGTE 14.25 SARVGNIPSSTSALKVPQLK VAE 10.255 NLVQRVPKDVFMGVDE 7.30 ASHLPFAQNISRVKE 7.726 GAILVVAATDGPMPQTRE 11.76 VYILSKDE 8.767 GGDALIPMLKE 9.26 TFNVGSFASGKE 5.768 KFMKIISLAPE 11.34 RYLGAKFPGAKRFSLE 7.759 VIAHLVNWE 10.22 AAKAKGAMALFGEKYDE 6.9810 RINKALDFIAE 8.25 GRQGGTLQLFRTE 4.2211 LRAKNQITLPVILKNE 5.03 KFTALTAELTAE 7.4412 GGRTVGAGVVAKVLS 6.3813 RFQADTLARFE 6.1514 FLKAGGVFTDE 6.573 of 9
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 smallest nanosphere down to a few tens of nanometers and the smallest
gap below the 5-nm range. To meet these fabrication requirements,
we combined two techniques: top-down and bottom-up (electron beam
lithography and metal electroless deposition) (30–32) (for process de-
tails, see Supplementary Materials, section 2). Use of high-resolution
electron beam lithography allows the best control of structure definition
and positioning, rendering the overall process controllable and repro-
ducible, whereas site-selective and self-assembling silver nanoparticle
electroless deposition (31, 33) is used for creating real 3D nanostructures
of appropriate size and shape. Figure 2 (A to C) reports the steps of the
process and shows representative scanning electron microscopy (SEM)
images of SSCs in four different configurations: monomer, dimer, trimer,
and tetramer (Fig. 2, E to H).
The fabrication process illustrated in Fig. 2 shows that, after the li-
thography process leading to the formation of nanoholes, a metal
site-selective growth (Fig. 2, A and B) forms the SSC. Figure 2C re-
ports the redox reactions responsible for silver nanosphere growth.
Figure 2 (E to H) presents SEM images of SSCs and higher architec-
tural combinations showing full fabrication control. The combination
of SSCs, from dimers to tetramers, can improve sensitivity detection
below picomolar concentrations. Here, we used only SSC monomers.Coluccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015This technology can easily be scaled up for mass production by using
imprinting as a parallel and low-cost lithography technique.LOCAL FIELD ENHANCEMENT OF SSC AND ROLE
OF DISORDER
Structural surface roughness or disorder is present on a scale much
smaller than the laser wavelength as a result of an intrinsic fabrication
mechanism. By using finite-difference time-domain (FDTD) analysis,
we investigated the role of disorder in sustaining energy localization
effects (34–40) (for details, see Supplementary Materials, section 3).
Figure 3 (A to C) shows a comparison between the ideal geometry and
our final disordered enhanced geometry (41). SSCmetrology values, such
as nanosphere sizes and gaps, were taken from actual fabricated devices.
Figure 3 shows a map of an electric field for two configurations of SSC.
In the first case, the SSCs are ideal, without surface roughness. In the
second case, an average roughness of 2 nm (measured by SEM on fab-
ricated SSCs) was introduced in the calculation. Furthermore, in both
cases, the smallest gap was 5 nm. From the comparison between the ideal
case and the fabricated SSC, we discovered that spatial localization
and field enhancement are further improved in the final devices.Fig. 2. Fabrication process of silver SSC. (A) After electron beam lithography and surface treatment with 2 M HF, the sample is immersed in HF/AgNO3
aqueous solution, where Ag+ is reduced to silver metal through a redox reaction chain. (B) In nanowells (reduction surface), silver growth follows a spherical
symmetry andgenerates three spheres of appropriate diameter and interdistance. (C) Redox reactions inside a nanowell starting from the silicon surface. (D) SSC
architecture and 2Dmap of electric field. Evidence of external laser polarization along the chain axis. The electric hotspot is localized in the smallest gap. (E toH)
SEM images of silver SSCs and possible combinations in monomer, dimer, trimer, and tetramer. Scale bars, 50 nm. PMMA, polymethyl methacrylate.4 of 9
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 In both situations, the results show an enhancement factor in the
electric field of around 100 (based on our fabricated geometry). The
results of Fig. 3C were based on a statistical ensemble of more than
200 different samples, which means that the effect of disorder is re-
producible and stable. Compared to surface-enhanced Raman scatter-
ing (SERS) measurements obtained after depositing a monolayer of
benzene-thiol molecules, this enhancement value is close to the exper-
imental value (about 107) (2, 42). Moreover, from the point of view of
localization field, it is important to consider another parameter (that
is, ratio e = Egap1/Egap2) between the fields Egap1 and Egap2, located in
the smallest gap and in the middle gap. As from Fig. 3C, the ratio e at
l = 514 nm is around 4 for the ideal SSC and 6 for the fabricated SSC
(Fig. 3A). Under uniform deposition of molecules over the whole SSC
device, the dominant Raman signal will originate from the molecules
located in the smallest gap. In fact, Raman intensity is proportional to
the fourth power (E4) of the local electric field. In the case of fabricated
SSCs, e4disordered = 6
4 = 1296; instead, e4ordered = 4
4 = 256.
Raman intensity is dominated by the scattering of molecules sitting in
the smallest hotspot. In a Raman experiment where SSC devices were used
as SERS building block, the intensity signal coming from the molecules in
the smallest gap was three orders of magnitude higher than the signal
coming from the intermediate gap (the intermediate gap is the only region
where a residual electric field is different from zero). As a consequence, we
can exploit this behavior of the SSC to assume that the detected signal came
fromthe smallest gap,without theneed for any aligningprocedure to locate
the molecules specifically in the hotspot. Therefore, if we randomly cover
the SSCs with molecules, the Raman signal detected is dominated by the
signal of the molecules sitting in the area defined by the smallest gap.DETECTION METHOD FOR ANALYSIS OF BRCA1
PEPTIDE MIXTURE
When the construct under examination is composed of a mixture of
different kinds of molecules, the number of molecules that can fit intoColuccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015the hotspot is directly related to their concentration in the solution
and to the volume of the hotspot. If we want to analyze a complex mix-
ture, we need to calibrate the concentration in such a way that the mu-
tual distance of the molecules after deposition is statistically in the range
of the linear size of the hotspot. In this way, only a few and a subset of
them will sit in the smallest gap after the solution has dried. In recon-
structing the whole content of the mixture, an m × n matrix array of
SSCs, whose m × n element is high enough to have all types of mol-
ecules statistically represented in the overall m × n pixel ensemble, is
necessary and sufficient.
The biomolecular procedure followed for extracting the peptides of
interest from BRCA1 led, after purification, to a mixture of two frac-
tions of 11 and 14 peptides, respectively. The experimental dilution
used fell in the range of 100 pM. At this concentration, few types of
molecules were deposited in each hotspot area, as indicated in the
analysis of Raman spectra (Figs. 1 and 4).
Detection of mutated peptides in BRCA1 after protein digestion
becomes an analytical problem of finding the elemental composition
of a multicomponent mixture. In this specific case, which is devoted to
detection of point mutation, we need a database where the Raman
spectra of each peptide component are known. In our procedure, this
database was created by acquiring each single peptide Raman spec-
trum (base element), and the multicomponent spectrum at each pixel
of the matrix was recovered by fitting it with a linear combination of
base elements.
Formally, a Raman spectrum, sM, can be fitted by the function:




where the index i runs through the number of peptides n (i = 1,…,m),
whereas j runs through the number of intervals n (j = 1,…,n).m is the
wave vector range in the Raman spectra. In Eq. 1, the coefficient xi,j
is the best combination that minimizes the sum of the squares ofFig. 3. Effects of disorder and sphere positioning on hotspot localization and enhancement. (A) Three-dimensional field enhancement and local-
ization of (top) ideal SSC with zero sphere roughness and (bottom) fabricated SSC with 2-nm surface roughness. (B) Two-dimensional field map with zero
roughness (top) and average surface disorder of 2 nm (bottom). (C) Comparison of enhancement between ideal SSC and fabricated SSC. A systematic
electric field enhancement of a factor of 2 (as a function of wavelength) is expected of a 2-nm disorder. E0 is the maximal field value used as normalization
factor in the 3D plot. In all simulations, laser polarization occurred along the SSC axis. au, arbitrary units; dis., disorder; ord., order.5 of 9
R E S EARCH ART I C L Edeviations of Y from the experimental values sM. From Eq. 1, the
mass fraction xi of the component i in the total solution is derived





 the higher is the content of the peptide i in the mixture. By repeating the
fitting procedure for all m × n matrix elements, all peptides extracted
from BRCA1 are recovered. With this procedure and because of high
SERS sensitivity, we could detect both wild-type and mutated species
in the mixtures. In Supplementary Materials, section 4, we report all data
obtained from the database and all data for the two mixtures, including
the relative c2 and coefficient of determination (r2) values. Figure 4 re-
ports a representative fit of the mixture at a specific pixel element of the
matrix. In this case, the Raman spectra contain three peptides.
The amount of peptide mixture derived from human samples was
0.2 ng/ml, with an average molarity of about 100 pM. The peptide
mixture was deposited on the plasmonic matrix, where it was air-dried
in a few tens of minutes.
As expected, any linear combination contains only a subset of the
25-peptide mixture (25 = 11 + 14) for the in vitro sample and a subset
of the 26-peptide mixture (11 + 15) for the synthetic sample.
The typical number of peptides in each pixel of the matrix is be-
tween 3 and 5. Therefore, collection of all pixel spectra allowed us to
fully reconstruct the mixture composition and, hence, to find the mu-
tated peptide in a patient carrying the disease.
Figure 5 reports additional details explaining SSC code arrays. On
the left, a SEM image of the 10 × 10 SSC array is shown (at this
magnification, only the overall matrix can be seen). Each pixel (aFig. 4. Linear combination fitting procedure of peptide spectra. Raman
spectra were collected in a representative pixel of the array. The fit gives a
weighted composition of peptides 1, 8, and 12. o
n
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ttp://advances.sciencem
ag.org/Fig. 5. Matrix array and data acquisition. (Top left) SEM image of a 10 × 10 SSC array. Scale bar, 2 mm. Each SSC represents a pixel element i,j of the
matrix. (Top right) In each pixel, color code is associated with a specific peptide. (Bottom left) A submatrix of 3 × 3 pixels is evidenced. Scale bar, 2 mm.
(Bottom right) A detailed SEM image of the SSC representing the pixel. Scale bar, 50 nm. Empty pixels represent specific positions in the array where no
peptides are detected.6 of 9





 single SSC) is represented by a color code depicting the linear com-
bination (the fit) of peptides found in that specific pixel. A 10 × 10
matrix is sufficient to fully reconstruct the original peptide mixture.
Figure 6 reports the Raman spectra of the peptide M1775 (wild
type and mutated from pure samples). The noticeable difference in
the spectra gives the distinction between wild-type species and mu-
tated species in the linear combination procedure. Furthermore, prin-
cipal components analysis (PCA) is performed on the Raman data set
constituting 2D maps of single pixels in the low-frequency range (43).
PCA is performed on the whole data set at once; consequently, the
computed principal components (PCs) are exactly the same for both
pixels, thus allowing a quantitative comparison of the Raman signa-
tures recorded over them. In particular, although the first PC (not
shown) is directly associated with the average signal over the two pix-
els, the second PC is instead related to the differences between the two
Raman signals. The 2D map of PC2 coefficients (Fig. 6C) shows two
different pixels: one dominated by the wild-type Raman signature (blue)
and the other dominated by the mutated signature (red). Figure 6D
shows the PC2 load curve, which takes into account the main differ-
ences between wild-type signals and mutated signals at once.
In this approach, we looked for peptide components, instead of
Raman signatures, of the whole BRCA1 protein. This analytical strat-
egy allows detection of even a single point mutation, namely, the ex-
change of a single amino acid in the peptide (in this case the exchangeColuccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015of a methionine with an arginine). The strategy of breaking a big pro-
tein into a mixture of peptides can be considered a general approach
that is applicable to other cases and disease typologies.
Details of the whole procedure are reported in Supplementary Ma-
terials, section 4, where we describe how the database (needed for Eq. 1 and
eqs. S4.1 to S4.4) was obtained. In Fig. 6D, we add a PCA calculation
to show quantitative discrimination between the Raman spectra of wild-
type peptides and the Raman spectra of mutated peptides. PCA qual-
ity confirms the net difference in the two Raman spectra.
The analytical results of the present procedure are reported in Table
1, where the analytical compositions of both mixtures, containing wild-
type and mutated peptides, are indicated (see Supplementary Materials,
section 5, complete list of peptides and corresponding IDs used for analy-
sis). These results were also compared with mass spectrometry results
for benchmarking. A full qualitative agreement between the two
methods was obtained despite the concentration and quantity of the
analytes being three orders of magnitude lower than those used in liquid
chromatography–tandemmass spectrometry (LC-MS/MS). The present
method is fully compatible with superhydrophobic devices, whose sen-
sitivity was proven to fall in the attomolar concentration range (44).
From the point of view of molecular medicine, detection of mu-
tated proteins (or their degradation products) in circulating plasma
is a challenging task. On the other hand, its demonstration that an al-
tered gene is transcribed and translated into an abnormal protein is o
n
 June 12, 2020
://advances.sciencem
ag.org/Fig. 6. Raman spectra of pure wild-type and mutated peptides. (A and B) Raman spectra (B) show a net difference between two peptides differ-
entiated by only the exchange of one amino acid (A; a methionine with an arginine). These spectra constitute the base set for the fitting procedure. Their
net difference allows identification of mutated peptides in the mixture. (C and D) The results of PCA are also shown: a 2D map of the PC2 coefficients of
two pixels (C), one pixel for each peptide, where color code is proportional to the significance of the PC2 parameter over the map; the PC2 parameter load
curve (D) takes into account spectral differences between the two peptides. The combination of PC2 mapping and PC2 load curve allows identification of
pixels dominated by wild-type or mutated species.7 of 9
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overy crucial to establishing a clear correlation between genotype and
phenotype. There is no linear relation between transcriptome and pro-
teome that is attributable to messenger RNA instability, microRNA
regulation of gene expression, and related modulatory mechanisms.
Therefore, it is likely that a specific gene bearing a mutation in its
coding sequence might never produce an abnormal protein.
The experimental strategy described in this work can overcome
limitations in detecting and identifying very low concentration pro-
teins or peptides in body fluid andmay therefore represent a tremendous
advancement in the early diagnosis of cancer and other degenerative dis-
eases. Moreover, this approach can be successfully applied to evaluate
drug response and prognosis in patients undergoing complex and
often debilitating treatments such as chemotherapy.
To the best of our knowledge, this is the first study to use plasmonics
to analyze in vitro human cancer samples with a high level of complex-
ity, such as a 25-component mixture at picomolar concentration. The
present method can be applied to a wider category of analytical pro-
blems in which both sensitivity and specificity are required. o
n





 MATERIALS AND METHODS
Sample preparation
In vitro wild-type and mutated BRCA1-BRCT protein domains were
obtained from plasmid construction and expression of recombinant
proteins. The two protein domains were digested by Glu-C enzyme and
analyzed by matrix-assisted laser desorption/ionization–time-of-flight
mass spectrometry (MALDI-TOF) performed on a Voyager-DE STR
(MALDI-TOF) (Applied Biosystems Inc.) equipped with a nitrogen
laser emitting at 337 nm. The two samples were fractionated by a
micro-HPLC system (Agilent Technologies), attaining wild-type and
mutated BRCA1-BRCT protein domains. Both fractionated samples
were injected by the QSTAR XL hybrid LC-MS/MS system (Applied
Biosystems Inc.). Finally, the data were searched on Mascot search en-
gine (www.matrixscience.com) version 2.2 against the International
Protein Index database version 3.58 (56,619 sequences). Detailed de-
scriptions of the extraction of BRCA1-BRCT protein domains are
available in Supplementary Materials, section 6. Synthetic BRCA1-BRCT
peptides (Table 1) were purchased from Sigma-Aldrich Corp. and
used without any further processing.
Samples (synthetic and in vitro) were dissolved in water. For SERS
measurements, plasmonic devices were immersed in the solution for
30 min, rinsed with water to wash out excess molecules, and dried
under nitrogen flow.
SSC fabrication
SSCs of silver nanospheres were realized by a combination of top-
down and bottom-up approaches. We combined high-resolution elec-
tron beam lithography and electroless deposition of silver, obtaining
metal nanostructures with spherical symmetry.
A high-resolution positive electron beam resist (PMMAA2;MicroChem)
was spin-coated on a clean silicon(100) substrate for 60 s at 5000 rpm
to obtain a 30-nm-thick layer and was prebaked at 170°C for 2 min
to remove the solvent from the resist. A pattern of 10 × 10 SSCs with
a 2-nm electron beam diameter was exposed by using an electron
beam lithography system (CABL-9000C; CRESTEC) working at 50 keV
acceleration voltage and 50 pA current. A dose of 1250 mC/cm2 was
set for exposure in a field of 60 mm by 60 mm. The sample was devel-Coluccio et al. Sci. Adv. 2015;1:e1500487 4 September 2015oped for immersion in isopropanol at 4°C to selectively remove the
exposed resist, rinsed with water, and dried under nitrogen flux.
Metallic silver was deposited on the patterned sample using an elec-
troless method involving silicon–silicon native oxide, hydrofluoric acid
(HF), water, and silver nitrate (AgNO3) (30, 31). The process was per-
formed in a few tens of seconds (30 to 40 s) by directly immersing the
silicon sample in an appropriate mixture of reactants (0.15 M HF and
0.05 mMAgNO3) at room temperature. After silver electroless deposition,
the wider gap became 20 to 25 nm and the smaller gap was below 5 nm.
Characterization technique
SEM images of nanostructures were recorded using the FEI Nova
600 NanoLab system. The acceleration voltage was kept between 5 and
15 keV in mode 2 configuration. In mode 2 configuration, the immer-
sion lens was turned on, and a through lens detector (TLD) in second-
ary electron operation was used.
Raman scattering measurements were performed using the Renishaw
InVia Raman spectrometer. Raman spectra were excited by a 514-nm
laser line (Ar+ laser) in backscattering configuration (150× objective)
and polarization along the axis of the SSC. Laser power and accumu-
lation time were kept at about 100 mW and 5 s, respectively. All Raman
data were analyzed using WiRE 3.2 built-in software.
Theoretical simulation
FDTD simulations were carried out using our home-made parallel code
NANOCPP (36), which scales up to hundreds of thousands of pro-
cessors. Dispersion of metals was carefully taken into account by using
a multipolar expansion that covers material response at visible and
infrared frequencies. The code for linear combination algorithm was
written in Matematica software and used for analyzing Raman spectra.SUPPLEMENTARY MATERIALS
Supplementary materials for this article are available at http://advances.sciencemag.org/cgi/
content/full/1/8/1500487/DC1
Crystallographic model of human BRCA1-BRCT protein
Fig. S1. Three-dimensional crystal structure of the BRCA1-BRCT protein.
Design and fabrication of device
Fig. S2. Top-down and bottom-up process fabrication.
Fig. S3. SEM images of different SSCs.
Theoretical comparison of ordered and disordered SSC device
Fig. S4. FDTD analysis of the role of disorder.
Complete peptide content of all the solutions resolved using the nanolens SERS device
Fig. S5. Nanolens matrix position of measurement points for the synthetic peptide solution.
Fig. S6. Nanolens matrix position of measurement points for the wild-type peptide solution.
Fig. S7. Nanolens matrix position of measurement points for the mutated peptide solution.
Table S1. Peptide fraction calculated for each measurement point in the grid of nanolens
devices and c2 and r2 statistics for the synthetic peptide solution.
Table S2. Relative content of each peptide in the synthetic peptide solution.
Table S3. Peptide fraction calculated for each measurement point in the grid of nanolens
devices and c2 and r2 statistics for the wild-type peptide solution.
Table S4. Relative content of each peptide in the wild-type peptide solution.
Table S5. Peptide fraction calculated for each measurement point in the grid of nanolens
devices and c2 and r2 statistics for the mutated peptide solution.
Table S6. Relative content of each peptide in the mutated peptide solution.
List of synthetic peptides utilized in the work and corresponding IDs
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